In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Joshua Brody(New York University), Ronald Levy(Hôpital Necker-Enfants Malades), Robert Tibshirani(Stanford University), Mia Levy(Rush University Medical Center), Weiyun Z. Ai(City College of San Francisco), James A. Torchia(Dana-Farber Cancer Institute), Ranjana H. Advani(Stanford Medicine), Richard T. Hoppe(Stanford Medicine), Irene Wapnir(Stanford Medicine), Susan J. Knox(Stanford University), Youn H. Kim(Stanford University), Debra K. Czerwinski(Stanford University), Lewis K. Shin(Ford Motor Company (United States))
Cited by 487
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k